Prescribing valproate to female patients under 18 years of age

Source:
Royal College of Paediatrics and Child Health - RCPCH
Publisher:
British Paediatric Neurology Association (BPNA);Royal College of Paediatrics and Child Health (RCPCH)
Publication date:
15 April 2019

Abstract

This joint guidance from the British Paediatric Neurology Association (BPNA) and the Royal College

of Paediatrics and Child Health (RCPCH) has been developed to provide greater clarity about the

approach to prescribing valproate in female patients under 18Uyears of age. The only licensed

indication for valproate in female children and young people is for the treatment of epilepsy. The

PREVENT programme is not relevant for many female children and young people due to their age

and learning ability. Whilst this guidance is structured around patient age and learning ability, the

age ranges are not prescriptive, and the guidance has been developed to support clinicians in the

implementation of an approach to practise that can support young girls as they transition through

childhood to adolescence and then adulthood.  Every patient and their family should have their

individual needs assessed and a bespoke approach undertaken that is broadly consistent with the

approach described in this guidance.